"T-Lymphocytes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen.
| Descriptor ID |
D013601
|
| MeSH Number(s) |
A11.118.637.555.567.569 A15.145.229.637.555.567.569 A15.382.490.555.567.569
|
| Concept/Terms |
T-Lymphocytes- T-Lymphocytes
- T Lymphocytes
- T-Lymphocyte
- T-Cells
- T Cells
- T-Cell
- Thymus-Dependent Lymphocytes
- Lymphocyte, Thymus-Dependent
- Lymphocytes, Thymus-Dependent
- Thymus Dependent Lymphocytes
- Thymus-Dependent Lymphocyte
|
Below are MeSH descriptors whose meaning is more general than "T-Lymphocytes".
Below are MeSH descriptors whose meaning is more specific than "T-Lymphocytes".
This graph shows the total number of publications written about "T-Lymphocytes" by people in this website by year, and whether "T-Lymphocytes" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 8 | 6 | 14 |
| 1997 | 12 | 7 | 19 |
| 1998 | 15 | 6 | 21 |
| 1999 | 18 | 9 | 27 |
| 2000 | 4 | 9 | 13 |
| 2001 | 20 | 7 | 27 |
| 2002 | 16 | 18 | 34 |
| 2003 | 21 | 12 | 33 |
| 2004 | 18 | 12 | 30 |
| 2005 | 11 | 9 | 20 |
| 2006 | 16 | 6 | 22 |
| 2007 | 19 | 13 | 32 |
| 2008 | 12 | 8 | 20 |
| 2009 | 18 | 17 | 35 |
| 2010 | 11 | 12 | 23 |
| 2011 | 22 | 12 | 34 |
| 2012 | 14 | 17 | 31 |
| 2013 | 23 | 12 | 35 |
| 2014 | 19 | 19 | 38 |
| 2015 | 25 | 18 | 43 |
| 2016 | 18 | 19 | 37 |
| 2017 | 16 | 9 | 25 |
| 2018 | 23 | 13 | 36 |
| 2019 | 17 | 11 | 28 |
| 2020 | 22 | 12 | 34 |
| 2021 | 10 | 14 | 24 |
| 2022 | 8 | 15 | 23 |
| 2023 | 8 | 17 | 25 |
| 2024 | 4 | 12 | 16 |
| 2025 | 17 | 8 | 25 |
| 2026 | 10 | 5 | 15 |
To return to the timeline,
click here.
Below are the most recent publications written about "T-Lymphocytes" by people in Profiles.
-
Low-Strength Type I Interferon Signaling Promotes CAR T-cell Treatment Efficacy. Cancer Immunol Res. 2026 Aug 04; 14(8):1292-1306.
-
Post-COVID impairment of T cell responses to community-acquired pathogens can be modified by activating cellular metabolism. PLoS Pathog. 2026 07; 22(7):e1013860.
-
CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study. Cancer Res Commun. 2026 07 01; 6(7):1681-1692.
-
Intravesical mesothelin-based CAR T cells targeting MUC16 effectively control bladder cancer in preclinical models. J Exp Med. 2026 Jul 06; 223(7).
-
Mitochondrial potential reflects T cell fitness and function during cancer immunotherapy. J Immunol. 2026 Jun 07; 215(6).
-
Efficacy and safety of durcabtagene autoleucel in a phase 1 trial for patients with relapsed/refractory multiple myeloma. Sci Transl Med. 2026 May 27; 18(851):eadx1799.
-
Tissue-specific tolerance mechanisms and lymph node co-drainage shape T cell immunity in the upper digestive system and pancreatic cancer progression. Cell Rep. 2026 May 26; 45(5):117324.
-
Therapeutic targeting of BCL-2 during CART cell production augments potency through non-apoptotic adaptive changes. Signal Transduct Target Ther. 2026 Apr 27; 11(1).
-
Genetically driven immune microenvironment states associate with therapeutic responses in MYD88 mutant lymphomas. Mol Cancer. 2026 Apr 20; 25(1).
-
Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy bb21217 for Relapsed and Refractory Multiple Myeloma: Results from the Phase I CRB-402 Study. Cancer Immunol Res. 2026 Apr 02; 14(4):528-542.